Importantly, the KRAS-mutant cancer cells independent of KRAS function, driven by mesenchymal reprogramming (high EMT gene signatures)2,16, exhibited significantly greater resistance to various MEK inhibitors (Fig. 1c). Here, KRAS is linked to cancer.